Advanced Biomed Inc. stock analysis
Advanced Biomed Inc. (ADVB) Stock Price & Analysis
ADVB Stock Chart & Stats
- Day’s Range
- $2.05 - $2.22
- 52-Week Range
- $1.80 - $24.23
- Previous Close
- $2.22
- Volume
- N/A
- Average Volume (3M)
- 65.56K
- Market Cap
- $3.47M
- Enterprise Value
- $5.08T
- Total Cash (Recent Filing)
- $214.00K
- Total Debt (Recent Filing)
- $1,878
- Price to Earnings (P/E)
- ―
- Beta
- 0.81
- Next Earnings
- N/A
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Advanced Biomed Inc. News
ADVB FAQ
What was Advanced Biomed Inc.’s price range in the past 12 months?
What is Advanced Biomed Inc.’s market cap?
When is Advanced Biomed Inc.’s upcoming earnings report date?
Is Advanced Biomed Inc. overvalued?
Does Advanced Biomed Inc. pay dividends?
What is Advanced Biomed Inc.’s EPS estimate?
How many shares outstanding does Advanced Biomed Inc. have?
Which hedge fund is a major shareholder of Advanced Biomed Inc.?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Advanced Biomed Inc.
Advanced Biomed Inc. functions as an investment holding company, primarily dedicated to the research and development of microfluidic biochip technologies. Based in Taiwan, the company leverages these innovations to enhance precision oncology, spanning cancer detection, diagnosis, and treatment. Its diverse product portfolio includes a suite of advanced devices: A+Pre: A fully automated system designed for pre-concentrating diluted blood samples. AC-1000: A rare cell device engineered to address the challenges of detecting cells in hypercoagulable samples from tumor patients. A+SCDrop: A specialized tool for capturing individual circulating tumor cells (CTCs). A+CellScan: An analyzer featuring an immunostaining chip, utilized for the immunostaining and analysis of output from the AC-1000. Beyond standalone devices, Advanced Biomed provides microfluidic biochips, including the A+Pre, AC-1000 CTC Enrichment, and A+CellScan chips, which are integral to delivering assay products and services to cancer patients. The company also offers a comprehensive range of immunochromogenic kits: A+CTCE kit: Used to identify epithelial circulating tumor cells by detecting EpCAM, CK (pan), CD45, and CD14 antibodies. A+CTCM kit: Targets mesenchymal circulating tumor cells through their expression of Vimentin, CD45, and CD14 antibodies. A+EMT kit: Designed for the identification of epithelial-to-mesenchymal circulating tumor cells, focusing on cell-surface Vimentin, CD45, and CD14 antibodies. A+CM kit: Facilitates the detection of tumor-associated macrophages by assessing PD-L1, CD45, and CD14 antibodies. In addition to its current offerings, Advanced Biomed is actively developing A+LCGuard, a promising solution for the early screening of lung cancer. The company further expands its presence by establishing and operating medical clinics in the People's Republic of China. Founded in 2014, Advanced Biomed Inc. maintains its corporate headquarters in New York, New York.
- Sector
- General
- Industry
- Medical - Diagnostics & Research
- CEO
- Xiaomin Chen
- Employees
- 12
- Website
- www.advb.ai
- Address
- 122 East 42nd Street, New York City, NY, 10168, US
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 1 | 6 | 15 |
| Technical Analysis | 1 | 6 | 3 |
| Moving Averages | 0 | 0 | 12 |










